ATE276241T1 - Antioxidationsmittel - Google Patents

Antioxidationsmittel

Info

Publication number
ATE276241T1
ATE276241T1 AT99972629T AT99972629T ATE276241T1 AT E276241 T1 ATE276241 T1 AT E276241T1 AT 99972629 T AT99972629 T AT 99972629T AT 99972629 T AT99972629 T AT 99972629T AT E276241 T1 ATE276241 T1 AT E276241T1
Authority
AT
Austria
Prior art keywords
compounds
antioxidant
ros
scavenging
properties
Prior art date
Application number
AT99972629T
Other languages
English (en)
Inventor
Abdullah Haj-Yehia
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE276241T1 publication Critical patent/ATE276241T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
AT99972629T 1998-11-25 1999-11-25 Antioxidationsmittel ATE276241T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11003798P 1998-11-25 1998-11-25
PCT/IL1999/000638 WO2000031060A1 (en) 1998-11-25 1999-11-25 Scavenger compounds

Publications (1)

Publication Number Publication Date
ATE276241T1 true ATE276241T1 (de) 2004-10-15

Family

ID=22330899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972629T ATE276241T1 (de) 1998-11-25 1999-11-25 Antioxidationsmittel

Country Status (9)

Country Link
US (1) US6900338B1 (de)
EP (1) EP1133487B1 (de)
JP (1) JP2002530396A (de)
AT (1) ATE276241T1 (de)
AU (1) AU775388B2 (de)
CA (1) CA2352144A1 (de)
DE (1) DE69920260T2 (de)
IL (1) IL143332A0 (de)
WO (1) WO2000031060A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US6365623B1 (en) * 1997-11-17 2002-04-02 Nicholas V. Perricone Treatment of acne using lipoic acid
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
DE10027968A1 (de) * 2000-06-08 2001-12-13 Asta Medica Ag Mittel zur Therapie von Demenzen
AU2003208767A1 (en) * 2002-03-05 2003-09-16 Universitaet Ulm Dithiolane derivatives for immobilizing biomolecules on noble metals and semiconductors
DE60302454T2 (de) 2002-04-19 2006-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
CA2679882C (en) 2007-03-08 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US9028874B2 (en) * 2008-01-03 2015-05-12 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
US8603531B2 (en) * 2008-06-02 2013-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of NSAIDs
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
EP2349279A4 (de) 2008-10-28 2013-12-25 Univ Leland Stanford Junior Aldehyddehydrogenase-modulatoren und anwendungsverfahren dafür
EP2364304A1 (de) * 2008-11-07 2011-09-14 ISTITUTO BIOCHIMICO NAZIONALE SAVIO s.r.l. Alpha-liponsäurederivate und ihre verwendung bei der herstellung von arzneimitteln
WO2010060098A1 (en) 2008-11-24 2010-05-27 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
TW201119651A (en) * 2009-10-26 2011-06-16 Lg Life Sciences Ltd Pharmaceutical composition comprising indole compound
WO2012021791A2 (en) * 2010-08-13 2012-02-16 Scidose Llc Aqueous formulation with improved stability
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120022147A1 (en) * 2011-08-17 2012-01-26 Krisani Biosciences (P) Ltd 2, 6 xylidine derivatives for the treatment of pain
WO2014084898A1 (en) 2012-11-28 2014-06-05 Yansong Lu Novel synthetic antioxidants and their uses
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US10501741B2 (en) 2014-06-25 2019-12-10 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (EMT) in cancer cells
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
CA3122246A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Synergistic compositions of bioactive agents for optimizing cellular health

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808480A (en) 1986-11-25 1989-02-28 Lehigh University Polymerizable heterocyclic disulfide-based compounds and membranes made therefrom
SE508601C2 (sv) * 1989-11-09 1998-10-19 Asta Medica Ag Läkemedel, vilka som aktiv substans innehåller karboxylsyror innehållande svavel samt deras användning för bekämpning av retrovirus
DE4417038A1 (de) 1994-05-14 1995-11-16 Carl Heinrich Dr Weischer Ester des Retinols (Vitamin A) und deren Herstellung und Verwendung als Arzneimittel und Kosmetika
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
IL142824A0 (en) * 1998-10-26 2002-03-10 Univ New York State Res Found Lipoic acid derivatives and their use in treatment of disease
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
DE19941217A1 (de) * 1999-08-30 2001-03-15 Asta Medica Ag Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs

Also Published As

Publication number Publication date
JP2002530396A (ja) 2002-09-17
AU775388B2 (en) 2004-07-29
DE69920260D1 (de) 2004-10-21
WO2000031060A1 (en) 2000-06-02
EP1133487B1 (de) 2004-09-15
DE69920260T2 (de) 2005-10-06
IL143332A0 (en) 2002-04-21
CA2352144A1 (en) 2000-06-02
EP1133487A1 (de) 2001-09-19
AU1406400A (en) 2000-06-13
US6900338B1 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
ATE276241T1 (de) Antioxidationsmittel
ATE253063T1 (de) 5-ht1f-agonisten
BRPI0410630A (pt) antagonista de nk1
BR9914044A (pt) ésteres tetrahidropirido
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
FI956119A0 (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
TR200101126T2 (tr) İkameli fenil türevleri, hazırlanma ve kullanımları
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
MX9702865A (es) Agentes estrogenicos.
ATE413388T1 (de) Muskarin antagonisten
BR0001292A (pt) Desfolhante
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
ATE386742T1 (de) Imidazonaphthyridine
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
IS5161A (is) Tetrahýdrópýridóefnasambönd
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE201204T1 (de) Derivate der thiazolidine-4-carbonsäure als cytoprotektive mittel
CY1106684T1 (el) Χρησιμοποιηση σκευασματων πουδρας που περιεχουν υδροξυπυριδονη για την αγωγη εξελκωσεων κνημης και εξελκωσεων λογω κατακλισης
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
EE9800230A (et) Difenüülstilbeenid kui COX-2 inhibiitorite eelravimid
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
NO20002408D0 (no) 5-HT1F antagonister
ATE455097T1 (de) Neue derivate von 4,4'-dithiobis-(3-aminobutan-1- sulfonaten) und diese enthaltende zusammensetzungen
DE69112070D1 (de) Anthelmintische und coccidizide 3-carbamoyl-4-hydroxycumarine, ihre verwendung und zusammensetzungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties